nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—RET—parathyroid gland—nephrolithiasis	0.0505	0.114	CbGeAlD
Ponatinib—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0302	0.0771	CcSEcCtD
Ponatinib—FGFR4—nephron tubule—nephrolithiasis	0.0226	0.051	CbGeAlD
Ponatinib—FGFR4—renal system—nephrolithiasis	0.0206	0.0463	CbGeAlD
Ponatinib—FGFR4—kidney—nephrolithiasis	0.0199	0.0448	CbGeAlD
Ponatinib—FGFR4—cortex of kidney—nephrolithiasis	0.0194	0.0436	CbGeAlD
Ponatinib—FGFR3—renal system—nephrolithiasis	0.014	0.0316	CbGeAlD
Ponatinib—FGFR3—kidney—nephrolithiasis	0.0136	0.0306	CbGeAlD
Ponatinib—BCR—nephron tubule—nephrolithiasis	0.0133	0.0301	CbGeAlD
Ponatinib—FGFR3—cortex of kidney—nephrolithiasis	0.0132	0.0298	CbGeAlD
Ponatinib—BCR—renal system—nephrolithiasis	0.0121	0.0274	CbGeAlD
Ponatinib—BCR—cortex of kidney—nephrolithiasis	0.0114	0.0258	CbGeAlD
Ponatinib—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0283	CcSEcCtD
Ponatinib—FGFR1—cortex of kidney—nephrolithiasis	0.0102	0.0229	CbGeAlD
Ponatinib—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0258	CcSEcCtD
Ponatinib—CYP3A4—urine—nephrolithiasis	0.00996	0.0225	CbGeAlD
Ponatinib—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00984	0.0251	CcSEcCtD
Ponatinib—CYP2D6—urine—nephrolithiasis	0.0098	0.0221	CbGeAlD
Ponatinib—RET—renal system—nephrolithiasis	0.00966	0.0218	CbGeAlD
Ponatinib—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00953	0.0243	CcSEcCtD
Ponatinib—RET—kidney—nephrolithiasis	0.00934	0.0211	CbGeAlD
Ponatinib—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00929	0.0237	CcSEcCtD
Ponatinib—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00924	0.0236	CcSEcCtD
Ponatinib—FGFR2—renal system—nephrolithiasis	0.00918	0.0207	CbGeAlD
Ponatinib—PDGFRA—Osteoblast Signaling—PTH—nephrolithiasis	0.00907	0.0552	CbGpPWpGaD
Ponatinib—FGFR2—kidney—nephrolithiasis	0.00888	0.02	CbGeAlD
Ponatinib—TEK—renal system—nephrolithiasis	0.0088	0.0198	CbGeAlD
Ponatinib—TEK—kidney—nephrolithiasis	0.00851	0.0192	CbGeAlD
Ponatinib—TEK—cortex of kidney—nephrolithiasis	0.00829	0.0187	CbGeAlD
Ponatinib—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00825	0.021	CcSEcCtD
Ponatinib—PDGFRA—renal system—nephrolithiasis	0.00797	0.018	CbGeAlD
Ponatinib—KDR—nephron tubule—nephrolithiasis	0.00791	0.0178	CbGeAlD
Ponatinib—SRC—renal system—nephrolithiasis	0.00782	0.0176	CbGeAlD
Ponatinib—SRC—kidney—nephrolithiasis	0.00756	0.017	CbGeAlD
Ponatinib—KDR—renal system—nephrolithiasis	0.00719	0.0162	CbGeAlD
Ponatinib—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00708	0.0181	CcSEcCtD
Ponatinib—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00702	0.0179	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00702	0.0179	CcSEcCtD
Ponatinib—KIT—nephron tubule—nephrolithiasis	0.00701	0.0158	CbGeAlD
Ponatinib—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00699	0.0178	CcSEcCtD
Ponatinib—KDR—kidney—nephrolithiasis	0.00695	0.0157	CbGeAlD
Ponatinib—KDR—cortex of kidney—nephrolithiasis	0.00677	0.0153	CbGeAlD
Ponatinib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00665	0.017	CcSEcCtD
Ponatinib—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00663	0.0169	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00663	0.0169	CcSEcCtD
Ponatinib—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00652	0.0166	CcSEcCtD
Ponatinib—TEK—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00652	0.0397	CbGpPWpGaD
Ponatinib—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.0064	0.0163	CcSEcCtD
Ponatinib—KIT—renal system—nephrolithiasis	0.00637	0.0144	CbGeAlD
Ponatinib—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00621	0.0158	CcSEcCtD
Ponatinib—KIT—kidney—nephrolithiasis	0.00616	0.0139	CbGeAlD
Ponatinib—ABL1—nephron tubule—nephrolithiasis	0.0061	0.0138	CbGeAlD
Ponatinib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00607	0.0155	CcSEcCtD
Ponatinib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00603	0.0154	CcSEcCtD
Ponatinib—KIT—cortex of kidney—nephrolithiasis	0.006	0.0135	CbGeAlD
Ponatinib—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00599	0.0153	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00597	0.0152	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00584	0.0149	CcSEcCtD
Ponatinib—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00576	0.0147	CcSEcCtD
Ponatinib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00561	0.0143	CcSEcCtD
Ponatinib—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00558	0.0142	CcSEcCtD
Ponatinib—ABL1—renal system—nephrolithiasis	0.00555	0.0125	CbGeAlD
Ponatinib—ABL1—kidney—nephrolithiasis	0.00536	0.0121	CbGeAlD
Ponatinib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00535	0.0137	CcSEcCtD
Ponatinib—FGFR4—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00534	0.0325	CbGpPWpGaD
Ponatinib—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00532	0.0136	CcSEcCtD
Ponatinib—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00527	0.0134	CcSEcCtD
Ponatinib—ABL1—cortex of kidney—nephrolithiasis	0.00522	0.0118	CbGeAlD
Ponatinib—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00517	0.0132	CcSEcCtD
Ponatinib—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00514	0.0131	CcSEcCtD
Ponatinib—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00503	0.0128	CcSEcCtD
Ponatinib—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.005	0.0128	CcSEcCtD
Ponatinib—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.005	0.0128	CcSEcCtD
Ponatinib—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00498	0.0127	CcSEcCtD
Ponatinib—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00496	0.0127	CcSEcCtD
Ponatinib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00482	0.0123	CcSEcCtD
Ponatinib—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00456	0.0116	CcSEcCtD
Ponatinib—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00452	0.0115	CcSEcCtD
Ponatinib—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00442	0.0113	CcSEcCtD
Ponatinib—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00425	0.0108	CcSEcCtD
Ponatinib—FGFR3—Endochondral Ossification—PTH—nephrolithiasis	0.0042	0.0256	CbGpPWpGaD
Ponatinib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00409	0.0104	CcSEcCtD
Ponatinib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00405	0.0103	CcSEcCtD
Ponatinib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00399	0.0102	CcSEcCtD
Ponatinib—FGFR3—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00395	0.0241	CbGpPWpGaD
Ponatinib—ABCG2—Iron uptake and transport—ATP6V0A4—nephrolithiasis	0.00391	0.0238	CbGpPWpGaD
Ponatinib—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00386	0.00984	CcSEcCtD
Ponatinib—ABCG2—nephron tubule—nephrolithiasis	0.00385	0.00868	CbGeAlD
Ponatinib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00978	CcSEcCtD
Ponatinib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00376	0.00959	CcSEcCtD
Ponatinib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00369	0.0094	CcSEcCtD
Ponatinib—CYP2C8—renal system—nephrolithiasis	0.0036	0.00811	CbGeAlD
Ponatinib—CYP3A5—nephron tubule—nephrolithiasis	0.00357	0.00806	CbGeAlD
Ponatinib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00357	0.00911	CcSEcCtD
Ponatinib—Cough—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00888	CcSEcCtD
Ponatinib—CYP2C8—kidney—nephrolithiasis	0.00348	0.00784	CbGeAlD
Ponatinib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00866	CcSEcCtD
Ponatinib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00866	CcSEcCtD
Ponatinib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00847	CcSEcCtD
Ponatinib—FGFR4—FGF signaling pathway—SPP1—nephrolithiasis	0.00327	0.0199	CbGpPWpGaD
Ponatinib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00326	0.0083	CcSEcCtD
Ponatinib—CYP3A5—renal system—nephrolithiasis	0.00325	0.00732	CbGeAlD
Ponatinib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00319	0.00813	CcSEcCtD
Ponatinib—FGFR4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00316	0.0192	CbGpPWpGaD
Ponatinib—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00315	0.00803	CcSEcCtD
Ponatinib—CYP3A5—kidney—nephrolithiasis	0.00314	0.00708	CbGeAlD
Ponatinib—CYP3A5—cortex of kidney—nephrolithiasis	0.00306	0.0069	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00756	CcSEcCtD
Ponatinib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00751	CcSEcCtD
Ponatinib—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00746	CcSEcCtD
Ponatinib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.0029	0.0074	CcSEcCtD
Ponatinib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00731	CcSEcCtD
Ponatinib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00283	0.00722	CcSEcCtD
Ponatinib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00716	CcSEcCtD
Ponatinib—Pain—Hydrochlorothiazide—nephrolithiasis	0.00278	0.0071	CcSEcCtD
Ponatinib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00278	0.0071	CcSEcCtD
Ponatinib—FGFR2—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00272	0.0165	CbGpPWpGaD
Ponatinib—FGFR1—Endochondral Ossification—PTH—nephrolithiasis	0.00269	0.0164	CbGpPWpGaD
Ponatinib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00266	0.00679	CcSEcCtD
Ponatinib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00257	0.00656	CcSEcCtD
Ponatinib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00257	0.00656	CcSEcCtD
Ponatinib—SRC—Cell-Cell communication—CLDN14—nephrolithiasis	0.00257	0.0156	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00253	0.0154	CbGpPWpGaD
Ponatinib—LYN—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00253	0.0154	CbGpPWpGaD
Ponatinib—KDR—Beta3 integrin cell surface interactions—SPP1—nephrolithiasis	0.00253	0.0154	CbGpPWpGaD
Ponatinib—CYP3A4—renal system—nephrolithiasis	0.00244	0.0055	CbGeAlD
Ponatinib—FGFR3—FGF signaling pathway—SPP1—nephrolithiasis	0.00242	0.0147	CbGpPWpGaD
Ponatinib—CYP2D6—renal system—nephrolithiasis	0.0024	0.00541	CbGeAlD
Ponatinib—CYP3A4—kidney—nephrolithiasis	0.00236	0.00531	CbGeAlD
Ponatinib—FGFR3—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00234	0.0142	CbGpPWpGaD
Ponatinib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00596	CcSEcCtD
Ponatinib—CYP2D6—kidney—nephrolithiasis	0.00232	0.00523	CbGeAlD
Ponatinib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00587	CcSEcCtD
Ponatinib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00223	0.00568	CcSEcCtD
Ponatinib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00549	CcSEcCtD
Ponatinib—FGFR3—Endochondral Ossification—SPP1—nephrolithiasis	0.00211	0.0128	CbGpPWpGaD
Ponatinib—LCK—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00207	0.0126	CbGpPWpGaD
Ponatinib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00207	0.00528	CcSEcCtD
Ponatinib—Rash—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00523	CcSEcCtD
Ponatinib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00523	CcSEcCtD
Ponatinib—Headache—Hydrochlorothiazide—nephrolithiasis	0.00204	0.0052	CcSEcCtD
Ponatinib—SRC—Cell-Cell communication—CLDN16—nephrolithiasis	0.00195	0.0119	CbGpPWpGaD
Ponatinib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00493	CcSEcCtD
Ponatinib—ABCB1—nephron tubule—nephrolithiasis	0.0019	0.00428	CbGeAlD
Ponatinib—KDR—Integrins in angiogenesis—SPP1—nephrolithiasis	0.00186	0.0113	CbGpPWpGaD
Ponatinib—SRC—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00183	0.0112	CbGpPWpGaD
Ponatinib—SRC—Alpha9 beta1 integrin signaling events—SPP1—nephrolithiasis	0.00183	0.0112	CbGpPWpGaD
Ponatinib—KDR—Integrin cell surface interactions—SPP1—nephrolithiasis	0.00179	0.0109	CbGpPWpGaD
Ponatinib—TEK—Hemostasis—SLC7A9—nephrolithiasis	0.00177	0.0108	CbGpPWpGaD
Ponatinib—TEK—Hemostasis—DGKH—nephrolithiasis	0.00177	0.0108	CbGpPWpGaD
Ponatinib—ABCB1—renal system—nephrolithiasis	0.00173	0.00389	CbGeAlD
Ponatinib—ABCB1—kidney—nephrolithiasis	0.00167	0.00376	CbGeAlD
Ponatinib—FGFR2—FGF signaling pathway—SPP1—nephrolithiasis	0.00166	0.0101	CbGpPWpGaD
Ponatinib—ABCB1—cortex of kidney—nephrolithiasis	0.00162	0.00366	CbGeAlD
Ponatinib—FGFR2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00161	0.00979	CbGpPWpGaD
Ponatinib—FGFR1—FGF signaling pathway—SPP1—nephrolithiasis	0.00155	0.00944	CbGpPWpGaD
Ponatinib—FGFR1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.0015	0.00912	CbGpPWpGaD
Ponatinib—PDGFRA—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00149	0.0091	CbGpPWpGaD
Ponatinib—SRC—Alpha4 beta1 integrin signaling events—SPP1—nephrolithiasis	0.00147	0.00893	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—ADCY10—nephrolithiasis	0.00138	0.00838	CbGpPWpGaD
Ponatinib—FGFR1—Endochondral Ossification—SPP1—nephrolithiasis	0.00135	0.00824	CbGpPWpGaD
Ponatinib—LYN—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00133	0.0081	CbGpPWpGaD
Ponatinib—BCR—Disease—SLC26A1—nephrolithiasis	0.00127	0.00772	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by PDGF—SPP1—nephrolithiasis	0.00124	0.00753	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—RGS14—nephrolithiasis	0.00117	0.00713	CbGpPWpGaD
Ponatinib—BCR—Disease—ATP6V0A4—nephrolithiasis	0.00113	0.00688	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00109	0.00664	CbGpPWpGaD
Ponatinib—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.00104	0.00632	CbGpPWpGaD
Ponatinib—SRC—FGF signaling pathway—SPP1—nephrolithiasis	0.000989	0.00602	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—ADCY10—nephrolithiasis	0.00097	0.00591	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000965	0.00588	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000921	0.00561	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000921	0.00561	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by PDGF—SPP1—nephrolithiasis	0.000915	0.00557	CbGpPWpGaD
Ponatinib—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000899	0.00547	CbGpPWpGaD
Ponatinib—FGFR4—Disease—SLC26A1—nephrolithiasis	0.000893	0.00544	CbGpPWpGaD
Ponatinib—SRC—Integrins in angiogenesis—SPP1—nephrolithiasis	0.000874	0.00533	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—RGS14—nephrolithiasis	0.000825	0.00502	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000821	0.005	CbGpPWpGaD
Ponatinib—FGFR4—Disease—ATP6V0A4—nephrolithiasis	0.000796	0.00485	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000791	0.00482	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—DGKH—nephrolithiasis	0.000791	0.00482	CbGpPWpGaD
Ponatinib—KDR—Focal Adhesion—SPP1—nephrolithiasis	0.00077	0.00469	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000751	0.00457	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000751	0.00457	CbGpPWpGaD
Ponatinib—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000738	0.00449	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ADCY10—nephrolithiasis	0.000718	0.00437	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—SLC7A9—nephrolithiasis	0.000686	0.00418	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—DGKH—nephrolithiasis	0.000686	0.00418	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—DGKH—nephrolithiasis	0.000682	0.00416	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—SLC7A9—nephrolithiasis	0.000682	0.00416	CbGpPWpGaD
Ponatinib—FGFR3—Disease—SLC26A1—nephrolithiasis	0.00066	0.00402	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by PDGF—SPP1—nephrolithiasis	0.000629	0.00383	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ADCY10—nephrolithiasis	0.000625	0.00381	CbGpPWpGaD
Ponatinib—KIT—Signaling by PDGF—SPP1—nephrolithiasis	0.000618	0.00376	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—RGS14—nephrolithiasis	0.00061	0.00372	CbGpPWpGaD
Ponatinib—KDR—Extracellular matrix organization—SPP1—nephrolithiasis	0.000592	0.0036	CbGpPWpGaD
Ponatinib—FGFR3—Disease—ATP6V0A4—nephrolithiasis	0.000589	0.00358	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by PDGF—SPP1—nephrolithiasis	0.000586	0.00357	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by PDGF—SPP1—nephrolithiasis	0.000585	0.00356	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—CHRM3—nephrolithiasis	0.000572	0.00348	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000569	0.00346	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000569	0.00346	CbGpPWpGaD
Ponatinib—PDGFRA—Focal Adhesion—SPP1—nephrolithiasis	0.000565	0.00344	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—SLC7A9—nephrolithiasis	0.000562	0.00342	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—DGKH—nephrolithiasis	0.000562	0.00342	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—DGKH—nephrolithiasis	0.000557	0.00339	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000557	0.00339	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—RGS14—nephrolithiasis	0.000532	0.00324	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000529	0.00322	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000529	0.00322	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—PTH—nephrolithiasis	0.000523	0.00318	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000498	0.00303	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000498	0.00303	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—SLC7A9—nephrolithiasis	0.000498	0.00303	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—DGKH—nephrolithiasis	0.000498	0.00303	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—GRHPR—nephrolithiasis	0.000494	0.00301	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ADCY10—nephrolithiasis	0.000494	0.00301	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ADCY10—nephrolithiasis	0.000485	0.00295	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000482	0.00294	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000471	0.00287	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000471	0.00287	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADCY10—nephrolithiasis	0.00046	0.0028	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADCY10—nephrolithiasis	0.000459	0.00279	CbGpPWpGaD
Ponatinib—FGFR2—Disease—SLC26A1—nephrolithiasis	0.000454	0.00277	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—SPP1—nephrolithiasis	0.000451	0.00275	CbGpPWpGaD
Ponatinib—KIT—Disease—SLC26A1—nephrolithiasis	0.000446	0.00272	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000444	0.0027	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AGXT—nephrolithiasis	0.000441	0.00268	CbGpPWpGaD
Ponatinib—FGFR1—Disease—SLC26A1—nephrolithiasis	0.000423	0.00258	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—SPP1—nephrolithiasis	0.000423	0.00257	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—SLC26A1—nephrolithiasis	0.000422	0.00257	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RGS14—nephrolithiasis	0.00042	0.00256	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RGS14—nephrolithiasis	0.000412	0.00251	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000412	0.00251	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DGKH—nephrolithiasis	0.000412	0.00251	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000406	0.00247	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000406	0.00247	CbGpPWpGaD
Ponatinib—FGFR2—Disease—ATP6V0A4—nephrolithiasis	0.000405	0.00247	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADCY10—nephrolithiasis	0.000405	0.00246	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—CHRM3—nephrolithiasis	0.000403	0.00245	CbGpPWpGaD
Ponatinib—KIT—Disease—ATP6V0A4—nephrolithiasis	0.000398	0.00242	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RGS14—nephrolithiasis	0.000391	0.00238	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RGS14—nephrolithiasis	0.00039	0.00238	CbGpPWpGaD
Ponatinib—FGFR1—Disease—ATP6V0A4—nephrolithiasis	0.000377	0.0023	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000377	0.00229	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—ATP6V0A4—nephrolithiasis	0.000376	0.00229	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—SLC26A1—nephrolithiasis	0.000375	0.00228	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—APRT—nephrolithiasis	0.000375	0.00228	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—SPP1—nephrolithiasis	0.000374	0.00228	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—PTH—nephrolithiasis	0.000368	0.00224	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—SPP1—nephrolithiasis	0.000362	0.0022	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DGKH—nephrolithiasis	0.000359	0.00219	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000359	0.00219	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RGS14—nephrolithiasis	0.000344	0.0021	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADCY10—nephrolithiasis	0.000332	0.00202	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GRHPR—nephrolithiasis	0.000327	0.00199	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000308	0.00187	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000308	0.00187	CbGpPWpGaD
Ponatinib—LCK—Disease—SLC26A1—nephrolithiasis	0.000305	0.00186	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CHRM3—nephrolithiasis	0.000298	0.00181	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADCY10—nephrolithiasis	0.000294	0.00179	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AGXT—nephrolithiasis	0.000291	0.00177	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000286	0.00174	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000286	0.00174	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000283	0.00173	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DGKH—nephrolithiasis	0.000283	0.00173	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RGS14—nephrolithiasis	0.000282	0.00172	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DGKH—nephrolithiasis	0.000278	0.0017	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000278	0.0017	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PTH—nephrolithiasis	0.000273	0.00166	CbGpPWpGaD
Ponatinib—LCK—Disease—ATP6V0A4—nephrolithiasis	0.000272	0.00166	CbGpPWpGaD
Ponatinib—SRC—Disease—SLC26A1—nephrolithiasis	0.00027	0.00165	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AQP1—nephrolithiasis	0.000267	0.00163	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000264	0.00161	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DGKH—nephrolithiasis	0.000264	0.00161	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DGKH—nephrolithiasis	0.000264	0.0016	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000264	0.0016	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—SPP1—nephrolithiasis	0.000263	0.0016	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CHRM3—nephrolithiasis	0.00026	0.00158	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000255	0.00155	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000255	0.00155	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RGS14—nephrolithiasis	0.00025	0.00152	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	0.000248	0.00151	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APRT—nephrolithiasis	0.000248	0.00151	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CHRM3—nephrolithiasis	0.000241	0.00147	CbGpPWpGaD
Ponatinib—SRC—Disease—ATP6V0A4—nephrolithiasis	0.000241	0.00147	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PTH—nephrolithiasis	0.000237	0.00145	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GRHPR—nephrolithiasis	0.000234	0.00143	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DGKH—nephrolithiasis	0.000232	0.00142	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000232	0.00142	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGXT—nephrolithiasis	0.000209	0.00127	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CHRM3—nephrolithiasis	0.000205	0.00125	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000204	0.00124	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.000203	0.00123	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CHRM3—nephrolithiasis	0.000201	0.00123	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CHRM3—nephrolithiasis	0.000191	0.00116	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DGKH—nephrolithiasis	0.000191	0.00116	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000191	0.00116	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CHRM3—nephrolithiasis	0.000191	0.00116	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTH—nephrolithiasis	0.000187	0.00114	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—SPP1—nephrolithiasis	0.000185	0.00113	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTH—nephrolithiasis	0.000184	0.00112	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.000181	0.0011	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	0.000177	0.00108	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APRT—nephrolithiasis	0.000177	0.00108	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000177	0.00108	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AQP1—nephrolithiasis	0.000176	0.00107	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTH—nephrolithiasis	0.000175	0.00106	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTH—nephrolithiasis	0.000174	0.00106	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000169	0.00103	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DGKH—nephrolithiasis	0.000169	0.00103	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CHRM3—nephrolithiasis	0.000168	0.00102	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000166	0.00101	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CHRM3—nephrolithiasis	0.00016	0.000972	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000157	0.000959	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTH—nephrolithiasis	0.000154	0.000936	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000154	0.000936	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000154	0.000936	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000148	0.000904	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CHRM3—nephrolithiasis	0.000138	0.000839	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—SPP1—nephrolithiasis	0.000137	0.000833	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000134	0.000815	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APRT—nephrolithiasis	0.000134	0.000815	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AQP1—nephrolithiasis	0.000126	0.00077	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000126	0.000768	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000126	0.000768	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTH—nephrolithiasis	0.000126	0.000767	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CHRM3—nephrolithiasis	0.000122	0.000743	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SPP1—nephrolithiasis	0.000119	0.000726	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CHRM3—nephrolithiasis	0.000114	0.000696	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTH—nephrolithiasis	0.000112	0.000679	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AQP1—nephrolithiasis	0.00011	0.000667	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000109	0.000663	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	9.9e-05	0.000603	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGXT—nephrolithiasis	9.7e-05	0.000591	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AQP1—nephrolithiasis	9.54e-05	0.000581	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SPP1—nephrolithiasis	9.41e-05	0.000573	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SPP1—nephrolithiasis	9.24e-05	0.000563	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AQP1—nephrolithiasis	8.99e-05	0.000547	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SPP1—nephrolithiasis	8.77e-05	0.000534	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SPP1—nephrolithiasis	8.75e-05	0.000533	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CHRM3—nephrolithiasis	8.63e-05	0.000525	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	8.25e-05	0.000502	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APRT—nephrolithiasis	8.25e-05	0.000502	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CHRM3—nephrolithiasis	8.13e-05	0.000495	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SPP1—nephrolithiasis	7.72e-05	0.00047	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—nephrolithiasis	6.32e-05	0.000385	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AQP1—nephrolithiasis	5.88e-05	0.000358	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—nephrolithiasis	5.6e-05	0.000341	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	5.32e-05	0.000324	CbGpPWpGaD
